Biogen Inc. reported total revenue of USD 2.28 billion for the fourth quarter (Q4) of 2025 and USD 9.89 billion for the full year (FY) 2025. Product revenue, net, reached USD 1.67 billion in Q4 and USD 7.12 billion for FY 2025. Revenue from anti-CD20 therapeutic programs was USD 521.2 million in Q4 and USD 1.86 billion for the full year. Alzheimer’s collaboration revenue totaled USD 47.1 million in Q4 and USD 177.7 million for FY 2025. Contract manufacturing, royalty, and other revenue was USD 43.8 million in Q4 and USD 732.9 million for the full year. Cost of sales, excluding amortization and impairment of acquired intangible assets, was USD 495.5 million in Q4 and USD 2.40 billion for FY 2025. Biogen Inc. highlighted that further financial considerations, including potential charges or gains related to acquisitions, business development transactions, or other significant events, may affect future results. The company also stated that a conference call and webcast to discuss the quarterly results will be held on February 6, 2026, with supplemental materials available on its website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on February 06, 2026, and is solely responsible for the information contained therein.